The so called @entity4352 antagonists or, more accurately, the @entity4352 modifiers are a rather heterogeneous set of drugs that work by several mechanisms. Such mechanisms include: (i) @entity1437 enzyme inhibition (e.g. zileuton); (ii) @entity1437 -activating-protein inhibition (e.g. quiflapon, @entity24985 ); (iii) @entity28575 antagonism (e.g. @entity22398 , @entity5203 , @entity7359 , @entity1440 ). The first @entity4352 modifiers tested (L-649,923 and tomelukast) had adverse gastrointestinal effects. Since then, several @entity4352 modifiers have been marketed, including @entity22398 , @entity7365 and montelukast. @entity22398 has been associated with 8 cases of @entity12534 , although these were probably not caused by @entity22398 . It is more likely that this syndrome is related to the underlying illness, which was masked by @entity288 , and revealed after @entity22398 -mediated @entity565 treatment allowed @entity134 withdrawal and unmasking of underlying @entity1333 . The main adverse effects of zileuton include liver function test abnormalities, while montelukast, the most recently marketed, has so far shown minimal adverse effects. @entity22398 causes a decrease in @entity1229 clearance and a clinically significant increase in prothrombin time, probably by cytochrome P450 isoenzyme interactions. Moreover, @entity9691 decreases @entity22398 maximum serum concentrations. @entity460 antagonists, @entity205 , @entity4392 and @entity11366 are metabolised via the cytochrome P450 system, and interactions with @entity4352 modifiers can be expected.

Tolerability of @entity4352 modifiers in XXXX : a review of clinical experience.

@entity4392 :: ('MESH:D020117', 'Chemical') :: ['cisapride'] @entity1437 :: ('240', 'Gene') :: ['5-lipoxygenase'] @entity11366 :: ('MESH:D016589', 'Chemical') :: ['astemizole'] @entity7359 :: ('MESH:C059141', 'Chemical') :: ['MK-571'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis'] @entity22398 :: ('MESH:C062735', 'Chemical') :: ['zafirlukast', 'Zafirlukast'] @entity12534 :: ('MESH:D015267', 'Disease') :: ['Churg-Strauss syndrome'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity4352 :: ('CHEBI:25029', 'Chemical') :: ['leukotriene'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids'] @entity7365 :: ('MESH:C063449', 'Chemical') :: ['zileuton'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity9691 :: ('MESH:D016593', 'Chemical') :: ['terfenadine'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['Calcium'] @entity1440 :: ('MESH:C047681', 'Chemical') :: ['pranlukast'] @entity24985 :: ('MESH:C079315', 'Chemical') :: ['BAYx 1005'] @entity5203 :: ('MESH:C093875', 'Chemical') :: ['montelukast'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin'] @entity28575 :: ('10800', 'Gene') :: ['LTD4-receptor']
@entity565 :: (MESH:D001249,Disease) :: ['asthma']
